Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents

European Journal of Medicinal Chemistry

Volumn 45, Issue 1, 2010, Pages 11-18

  Shen, Li ^a   Yang, Xiaochun ^a   Yang, Bo ^a   He, Qiaojun ^a   Hu, Yongzhou ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Anti proliferative; Combretastatin A 4; Cytotoxic; Hybrids; Lamellarin D

Indexed keywords

2 (3 ISOPROPOXY 4 METHOXYPHENYL) 8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (4 BROMOPHENYL) 8 ISOPROPOXY 9 METHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (4 BROMOPHENYL) 8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (4 CHLOROPHENYL) 8 ISOPROPOXY 9 METHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (4 CHLOROPHENYL) 8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (5 FLUORO 2 ISOPROPOXYPHENYL) 8,9 DIMETHOXY 1 (4 METHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (5 FLUORO 2 METHOXYPHENYL) 8 ISOPROPOXY 1 (4 ISOPROPOXY 3 METHOXYPHENYL) 9 METHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (5 FLUORO 2 METHOXYPHENYL) 8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 (5 FLUORO 2 METHOXYPHENYL) 8,9 DIMETHOXY 1 (4 ISOPROPOXY 3 METHOXYPHENYL) 9 METHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; 2 [1 (3,4 DIMETHOXYPHENYL) 8,9 DIMETHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL] 4,5 DIMETHOXYPHENYLMETHANESULFONATE; 2 [8 ISOPROPOXY 1 (4 ISOPROPOXY 3 METHOXYPHENYL) 9 METHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLIN 2 YL] 4,5 DIMETHOXYPHENYLMETHANESULFONATE; 4 [1 (3,4 DIMETHOXYPHENYL) 8,9 DIMETHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]BENZENE 1,2 DIOL; 4 [8 ISOPROPOXY 1 (4 ISOPROPOXY 3 METHOXYPHENYL) 9 METHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]BENZENE 1,2 DIOL; 4 [8 ISOPROPOXY 9 METHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]BENZENE 1,2 DIOL; 4 [8 ISOPROPOXY 9 METHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]PHENOL; 4 [8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]BENZENE 1,2 DIOL; 4 [8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]PHENOL; 4 [8,9 DIMETHOXY 1 (4 METHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]PHENOL; 5 [8 ISOPROPOXY 9 METHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL] 2 METHOXYPHENOL; 5 [8,9 DIMETHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL] 2 METHOXYPHENOL; 5 [8,9 DIMETHOXY 1 (4 METHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL]2 METHOXYPHENOL; 5 ISOPROPOXY 2 [8 ISOPROPOXY 1 (4 ISOPROPOXY 3 METHOXYPHENYL) 9 METHOXY 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE 2 YL] 4 METHOXYPHENYLMETHANESULFONATE; 8 ISOPROPOXY 2 (3 ISOPROPOXY 4 METHOXYPHENYL) 9 METHOXY 1 (3,4,5 TRIMETHOXYPHENYL) 5,6 DIHYDROPYRROLO[2,1 A]ISOQUINOLINE; COMBRETASTATIN A4 DERIVATIVE; CYTOTOXIC AGENT; LAMELLARIN D DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN K 562; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50;

CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; CYTOTOXINS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STILBENES;

EID: 72049095563     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.09.017     Document Type: Article

References (25)

1. Andersen R.J., Faulkner D.J., He C.H., Van Duyne G.D., and Clardy J. J. Am. Chem. Soc. 107 (1985) 5492
2. Facompré M., Tardy C., Bal-Mahieu C., Colson P., Perez C., Manzanares I., Cuevas C., and Bailly C. Cancer Res. 63 (2003) 7392
3. Vanhuyse M., Kluza J., Tardy C., Otero G., Cuevas C., Bailly C., and Lansiaux A. Cancer Lett. 221 (2005) 165
4. Kluza J., l Gallego M.A., Loyens A., Beauvillain J.C., Sousa-Faro J.M.F., Cuevas C., Marchetti P., and Bailly C. Cancer Res. 66 (2006) 3177
5. Ishibashi F., Tanabe S., Oda T., and Iwao M. J. Nat. Prod. 65 (2002) 500
6. Bailly C. Curr. Med. Chem. -Anti-Cancer Agents. 4 (2004) 363
7. Handy S.T., and Zhang Y.A. Org. Prep. Proced. Int 37 (2005) 411
8. Fan H., Peng J.N., Hamann M.T., and Hu J.F. Chem. Rev. 108 (2008) 264
9. Pla D., Albericio F., and Alvarez M. Anti-Cancer Agents in Med. Chem. 8 (2008) 746
10. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garcia-Kendall D. Experientia. 45 (1989) 209
11. Lin C.M., Singh S.B., Chu P.S., Dempcy R.O., Schmidt J.M., Pettit G.R., and Hamel E. Mol. Pharmacol. 34 (1988) 200
12. Lin C.M., Ho H.H., Pettit G.R., and Hamel E. Biochem. 28 (1989) 6984
13. . An Oxigene′s report on http://www.oxigene.com/vascular/pipeline.asp (Clinical Research Progress of CA4P, June 2006)
14. Banwell M.G., Hamel E., Hockless D.C.R., Verdier-Pinard P., Willis A.C., and Wong D.J. Bioorg. Med. Chem. 14 (2006) 4627
15. Ruchirawat S., and Mutarapat T. Tetrahedron Lett. 42 (2001) 1205
16. Ploypradith P., Jinaglueng W., Pavaro C., and Ruchirawat S. Tetrahedron Lett. 44 (2003) 1363
17. You Y.C., Yang G., Wang A.L., and Li D.P. Curr. Appl. Phys. 5 (2005) 535
18. You Y.C., Wang A.L., Li D.P., and Yang G. Biomed. Mater. (2006) 1 L7
19. Chai C.L.L., Elix J.A., and Moore F.K.E. J. Org. Chem. 71 (2006) 992
20. Batra S., Sabnis Y.A., and Rosenthal P.J. Bioorg. Med. Chem. 11 (2003) 2293
21. Varma R.S., and Kabalka G.W. Syn.Commun. 15 (1985) 843
22. Pla D., Marchal A., Olsen C.A., Francesch A., Cuevas C., Albericio F., and Álvarez M. J. Med. Chem. 49 (2006) 3257
23. Armarego W.L.F., and Chai C.L.L. Purification of Laboratory Chemicals. fifth ed. (2003), Butterworth -Heinemann, Oxford, New York
24. Milhazes N., Calheiros R., Marques M.P.M., Garrido J., Cordeiro M.N.D.S., Rodrigues C., Quinteira S., Novais C., Peixe L., and Borges F. Bioorg. Med. Chem. 14 (2006) 4078
25. Fujikawa N., Ohta T., Yamaguchi T., Fukuda T., Ishibashi F., and Iwao M. Tetrahedron 62 (2006) 594